Image of the Day: Membrane Fever 

Scientists have discovered a mechanism by which the Rift Valley fever virus infects the cells of its hosts.

By | November 17, 2017

A model of the Rift Valley virus fusion protein (in yellow, blue, and red in the lower half) interacting with a cell membrane (shown in white and green). The enlargement shows a “pocket” in the membrane (yellow) where the two connect. PABLO GUARDAVO-CALVO / INSTITUT PASTEURRift Valley fever—a disease endemic to sub-Saharan Africa—primarily affects livestock, but can also be fatal in humans. Scientists don’t quite understand how the virus responsible for the disease infects the cells of its hosts. Now, scientists from Germany and France have discovered a mechanism by which the virus inserts itself into the host membrane: One of its proteins has a “pocket” that recognizes specific lipids in cellular membranes. Similar proteins are found in other viruses such as Zika and chikungunya.

P. Guardado-Calvo et al., “A glycerophospholipid-specific pocket in the RVFV class II fusion protein drives target membrane insertion,” Science, doi:10.1126/science.aal2712, 2017.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Gaining and Losing Weight Affects the Body
    Daily News How Gaining and Losing Weight Affects the Body

    Millions of measurements from 23 people who consumed extra calories every day for a month reveal changes in proteins, metabolites, and gut microbiota that accompany shifts in body mass.

  2. That Other CRISPR Patent Dispute
    Daily News That Other CRISPR Patent Dispute

    The Broad Institute and Rockefeller University disagree over which scientists should be named as inventors on certain patents involving the gene-editing technology.

  3. Neurons Use Virus-Like Proteins to Transmit Information
  4. EPO Revokes Broad’s CRISPR Patent
    The Nutshell EPO Revokes Broad’s CRISPR Patent

    Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely—and more are likely to follow.